~3 spots leftby Mar 2026

9-ING-41 for Myelofibrosis

Recruiting in Palo Alto (17 mi)
+10 other locations
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Actuate Therapeutics Inc.
No Placebo Group
Prior Safety Data

Trial Summary

What is the purpose of this trial?9-ING-41 has anti-cancer clinical activity while not causing myelosuppression, and has both pre-clinical anti-fibrotic activity and activity against myelofibrosis. This Phase 2 study will study its efficacy in patients with advanced myelofibrosis.

Eligibility Criteria

Adults with advanced myelofibrosis who've tried Ruxolitinib for at least 12 weeks without success can join this trial. They must have proper organ function, not be pregnant or breastfeeding, and agree to use contraception. Excluded are those with recent heart attacks, hypersensitivity to the drug's components, vulnerable populations like prisoners, or using certain herbal medications.

Inclusion Criteria

Patient is aged ≥ 18 years
Patient has documented diagnosis of symptomatic primary MF, PPV-MF or PET-MF as defined by the World Health Organization classification
Patient is ineligible or unwilling to undergo stem cell transplantation at time of study entry
Patient has adequate performance status (PS): Eastern Co-operative Oncology Group (ECOG) PS 0-2

Exclusion Criteria

You had a heart attack within the past 12 weeks before starting the medication 9-ING-41.
Herbal preparations / medications are prohibited throughout the study. These herbal medications include, but are not limited to St. John's wort, Kava, ephedra (ma huang), Gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and Ginseng. Patients should stop using cannabinoids or herbal preparations/medications at least 7 days prior to first dose of study treatment

Participant Groups

The study is testing the effectiveness of a new treatment called 9-ING-41 in patients with advanced myelofibrosis. It's being given alongside Ruxolitinib—a previously attempted therapy—to see if it improves patient outcomes without causing additional bone marrow suppression.
2Treatment groups
Experimental Treatment
Group I: 9-ING-41 plus RuxolitinibExperimental Treatment2 Interventions
9-ING-41 9.3 mg/kg will be administered by intravenous infusion twice weekly for cycle durations of 28 days with Ruxolitinib at doses specified in the protocol as appropriate for patient's platelet count.
Group II: 9-ING-41Experimental Treatment1 Intervention
9-ING-41 is administered by intravenous infusion twice weekly at a dose of 9.3 mg/kg. Cycle duration is 28 days.

Find A Clinic Near You

Research locations nearbySelect from list below to view details:
Cleveland ClinicCleveland, OH
Winship Cancer Institute, Emory UniversityAtlanta, GA
Georgia Cancer CenterAugusta, GA
Weill Cornell Medicine | NewYork-Presbyterian Meyer Cancer CenterNew York, NY
More Trial Locations
Loading ...

Who is running the clinical trial?

Actuate Therapeutics Inc.Lead Sponsor

References